Deutsche Bank Maintains Buy on Ceridian HCM Holding, Lowers Price Target to $85
Deutsche Bank analyst Brad Zelnick maintains Ceridian HCM Holding (NYSE:CDAY) with a Buy and lowers the price target from $105 to $85.
Piper Sandler Maintains Neutral on Ceridian HCM Holding, Lowers Price Target to $61
Piper Sandler analyst Arvind Ramnani maintains Ceridian HCM Holding (NYSE:CDAY) with a Neutral and lowers the price target from $85 to $61.
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Buy, Sell Or Hold? Netflix, PayPal And The 6 Worst-Performing Stocks Of 2022
The SPDR S&P 500 ETF Trust (NYSE: SPY) is off to a horrible start to 2022, down 11.7% year-to-date. However, a handful of popular stocks have severely lagged the market and generated much heavier losses for investors this year.
Analyst Ratings for Ceridian HCM Holding
Within the last quarter, Ceridian HCM Holding (NYSE:CDAY) has observed the following analyst ratings:
Credit Suisse Initiates Coverage On Ceridian HCM Holding with Outperform Rating, Announces Price Target of $85
Credit Suisse analyst Kevin Mcveigh initiates coverage on Ceridian HCM Holding (NYSE:CDAY) with a Outperform rating and announces Price Target of $85.
What 9 Analyst Ratings Have To Say About Ceridian HCM Holding
Analysts have provided the following ratings for Ceridian HCM Holding (NYSE:CDAY) within the last quarter: